Revvity, Inc. has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases, according to an announcement.

The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026 and is subject to customary closing conditions, including required regulatory approvals. Additional terms of the transaction were not disclosed.

HCD’s flagship EndoC-βH5 human pancreatic beta cell model is designed to provide researchers with a human-relevant model for studying beta cell physiology and function across diabetes and obesity research. HCD also offers specialized media and reagents, preclinical research, and its proprietary NatLine cell-line development platform, which supports the development of functionally consistent human cell models.

EndoC-βH5 cells are well-suited for use with Revvity’s HTRF and AlphaLISA assays for measuring key pharmacological readouts such as cAMP and insulin as well as pHSense technology for receptor internalization studies. The combination also extends to Revvity’s ATPlite assays for cell viability and proliferation analysis. These detection and analysis capabilities are expected to extend to Revvity’s high-content screening platform.

HCD’s technology also has applications beyond early-stage discovery, including research supporting regenerative medicine approaches for Type 1 diabetes and quality control activities as cell-based therapies progress toward commercialization. Upon completion of the acquisition, the combined solutions are expected to create an opportunity to support customers across multiple stages of therapeutic research and development.

Visit Revvity for more information